To update oncologists on pathogenesis, contemporary diagnosis, risk stratification, and
treatment strategies in BCR-ABL1–negative myeloproliferative neoplasms, including …

Recent advances in our understanding of the pathogenesis of the Philadelphia chromosome-
negative myeloproliferative neoplasms, polycythaemia vera, essential thrombocythaemia …

Purpose Myelofibrosis is a myeloid malignancy associated with anemia, splenomegaly, and
constitutional symptoms. Patients frequently harbor JAK-STAT activating mutations that are …

Thrombopoietin (TPO) is the cytokine that is chiefly responsible for megakaryocyte
production but increasingly attention has turned to its role in maintaining hematopoietic stem …

Philadelphia chromosome–negative myeloproliferative neoplasms (MPNs) are clonal
myeloid disorders with increased production of terminally differentiated cells. The disease …

Thrombocytosis is a commonly encountered clinical scenario, with a large proportion of
cases discovered incidentally. The differential diagnosis for thrombocytosis is broad and the …

The field of Philadelphia-chromosome-negative chronic myeloproliferative neoplasms
(MPNs) has recently witnessed tremendous advances in the basic knowledge of disease …

The discovery of JAK2V617F has rejuvenated interest in Janus kinase (JAK)-signal
transducer and activator of transcription (STAT), both as an oncogenic pathway and a drug …

Ligand binding to the thrombopoietin receptor is thought to stabilize an active receptor dimer
that regulates megakaryocyte differentiation and platelet formation, as well as …

A substantial body of evidence supports a role for the growth hormone (GH)–IGF-1 axis in
cancer incidence and progression. This includes epidemiological evidence relating elevated …